EA201290442A1 - Композиция и способы профилактики и лечения макулярной дегенерации, диабетической ретинопатии и диабетического макулярного отека - Google Patents

Композиция и способы профилактики и лечения макулярной дегенерации, диабетической ретинопатии и диабетического макулярного отека

Info

Publication number
EA201290442A1
EA201290442A1 EA201290442A EA201290442A EA201290442A1 EA 201290442 A1 EA201290442 A1 EA 201290442A1 EA 201290442 A EA201290442 A EA 201290442A EA 201290442 A EA201290442 A EA 201290442A EA 201290442 A1 EA201290442 A1 EA 201290442A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetic
bruch
stabilization
methods
membrane
Prior art date
Application number
EA201290442A
Other languages
English (en)
Inventor
Дэйл П. Девор
Брюс Х. Девулфсон
Вэнс Томпсон
Original Assignee
Юклид Системз Корпорэйшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юклид Системз Корпорэйшн filed Critical Юклид Системз Корпорэйшн
Publication of EA201290442A1 publication Critical patent/EA201290442A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Представлены способы стабилизации и организации коллагеновых фибрилл во внеклеточном матриксе ткани сетчатки, в частности, в мембране Бруха, и стабилизации слоев пигментного эпителия сетчатки, выстилающих мембрану Бруха. Стабилизация и организация могут быть осуществлены путем лечения ткани сетчатки белком, который сшивает и организует фибриллы коллагена, таким как декорин. Способы стабилизации и организации включают лечение тканей сетчатки до, во время или после постановки диагноза сухой макулярной дегенерации, диагностики ранних стадий диабетической ретинопатии и диабетического макулярного отека, чтобы предотвратить, задержать или ограничить прогрессирование дезорганизации мембраны Бруха и дезорганизации клеток пигментного эпителия сетчатки, выстилающих мембрану Бруха.
EA201290442A 2009-12-04 2010-12-03 Композиция и способы профилактики и лечения макулярной дегенерации, диабетической ретинопатии и диабетического макулярного отека EA201290442A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26670509P 2009-12-04 2009-12-04
US32941010P 2010-04-29 2010-04-29
PCT/US2010/058856 WO2011069046A1 (en) 2009-12-04 2010-12-03 Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema

Publications (1)

Publication Number Publication Date
EA201290442A1 true EA201290442A1 (ru) 2012-11-30

Family

ID=44115308

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290442A EA201290442A1 (ru) 2009-12-04 2010-12-03 Композиция и способы профилактики и лечения макулярной дегенерации, диабетической ретинопатии и диабетического макулярного отека

Country Status (12)

Country Link
US (1) US20130045926A1 (ru)
EP (1) EP2506862A4 (ru)
JP (1) JP2013512924A (ru)
KR (1) KR20120114282A (ru)
CN (1) CN102639141A (ru)
AU (1) AU2010325908A1 (ru)
BR (1) BR112012013303A2 (ru)
CA (1) CA2781309A1 (ru)
EA (1) EA201290442A1 (ru)
IL (1) IL219534A0 (ru)
MX (1) MX2012005973A (ru)
WO (1) WO2011069046A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2720368T3 (es) 2008-03-27 2019-07-19 Purdue Research Foundation Peptidoglicanos sintéticos de enlace a colágeno, preparación y método de utilización
AU2012258706B2 (en) 2011-05-24 2017-05-18 Symic OA ApS Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
JP2015509500A (ja) * 2012-02-22 2015-03-30 ステルス ペプチドズ インターナショナル インコーポレイテッド 眼疾患を予防または治療するための方法および組成物
US9200039B2 (en) 2013-03-15 2015-12-01 Symic Ip, Llc Extracellular matrix-binding synthetic peptidoglycans
US10772931B2 (en) 2014-04-25 2020-09-15 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
CN109073660B (zh) * 2016-02-29 2022-10-28 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物
CA3035675C (en) 2016-09-09 2023-06-13 Curogene Life Sciences Co., Ltd Pharmaceutical composition containing mtor inhibitor for treating macular degeneration
ES2965670T3 (es) * 2017-02-09 2024-04-16 Altregen Co Ltd Composición que comprende extracto compuesto de ginseng/ginseng rojo y pepino de mar como ingrediente eficaz para prevenir o tratar la enfermedad relacionada con la hipofunción de la membrana de Bruch
EP3648774A4 (en) 2017-07-07 2021-04-21 Symic IP, LLC SYNTHETIC ORGANIC CONJUGATES
WO2019229116A1 (en) 2018-05-31 2019-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Intravitreal delivery of a decorin polypeptide for the treatment of choroidal neovascularisation
CA3110040A1 (en) * 2018-09-14 2020-03-19 Universiteit Gent Compositions for use to treat advanced glycation end products-dependent ocular diseases
FR3090320B1 (fr) * 2018-12-19 2023-03-03 Karim Bouzakri Utilisation de la decorine dans le traitement du diabete

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673341B2 (en) * 1998-07-06 2004-01-06 Beth Israel Deaconness Medical Center Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis
IL143243A0 (en) * 1998-11-19 2002-04-21 Organogenesis Inc A cultured tissue construct containing fibroblast cells and methods for the production thereof
KR100720291B1 (ko) * 1999-09-15 2007-05-21 브루스 에이치 드울프손 각막굴절교정용 렌즈의 착용중 또는 착용후에 각막 조직을안정화시키기 위한 조성물
US6946440B1 (en) * 1999-09-15 2005-09-20 Dewoolfson Bruce H Composition for stabilizing corneal tissue during or after orthokeratology lens wear
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
WO2004105784A1 (en) * 2003-05-29 2004-12-09 The University Of Manchester Class iii slrp agonists for the reduction of blood vessel formation
JP2008503205A (ja) * 2004-05-31 2008-02-07 ナショナル ユニヴァーシティ オブ シンガポール デコリンロイシンリッチリピート由来のペプチドおよびその使用
ATE461696T1 (de) * 2004-11-09 2010-04-15 Alcon Inc 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
US20070282282A1 (en) * 2004-11-23 2007-12-06 Wong Edward K Jr Medical device and method for temperature control and treatment of the eye and surrounding tissues
US20090203590A1 (en) * 2005-05-27 2009-08-13 Children's Medical Center Corporation Method for the inhibition of angiogenesis
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2008080110A1 (en) * 2006-12-21 2008-07-03 Alcon, Inc. Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
CN101333252A (zh) * 2008-08-06 2008-12-31 温州医学院 能抑制肿瘤细胞生长和转移的饰胶蛋白及其制备方法和应用

Also Published As

Publication number Publication date
IL219534A0 (en) 2012-06-28
CN102639141A (zh) 2012-08-15
WO2011069046A1 (en) 2011-06-09
MX2012005973A (es) 2012-06-25
US20130045926A1 (en) 2013-02-21
KR20120114282A (ko) 2012-10-16
EP2506862A1 (en) 2012-10-10
JP2013512924A (ja) 2013-04-18
BR112012013303A2 (pt) 2016-03-01
CA2781309A1 (en) 2011-06-09
EP2506862A4 (en) 2013-05-29
AU2010325908A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
EA201290442A1 (ru) Композиция и способы профилактики и лечения макулярной дегенерации, диабетической ретинопатии и диабетического макулярного отека
Wollensak et al. Interlamellar cohesion after corneal crosslinking using riboflavin and ultraviolet A light
BRPI0613401B8 (pt) composição oftálmica compreendendo derivados de glicocorticoides que penetram seletivamente nos tecidos do segmento posterior
EA201170551A1 (ru) Способы лечения заболеваний глаз
MY169328A (en) Compositions for the treatment of dry eye
WO2012002986A3 (en) Decellularized and delipidized extracellular matrix and methods of use
MX336944B (es) Medicamento para el tratamiento de la queratitis seca caracterizada por combinar el agonista del receptor p2y2 y acido hialuronico o una sal del mismo, metodos para tratar la queratitis seca, y uso del agonista del receptor p2y2 y acido hialuronico o una sal del mismo.
EA200971116A1 (ru) Способ желатинизации фиброина шелка с применением обработки ультразвуком
CO6390041A2 (es) Agentes y antagonistas fijaodres de notch y metodos para el uso de los mismos.
MX358504B (es) Lagrimas artificiales y usos terapeuticos.
BR112014026090A8 (pt) composição de matriz tecidual apta a fluir
BRPI0518247A2 (pt) composiÇÕes compreendo inibidores de cinases jun n-terminais e uso
AR079572A1 (es) Anticuerpos que se enlazan a los epitopos de un polipeptido wise
BR112013026976A2 (pt) alfa glucosidade ácida modificada com processamento acelerado
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
MX2020004076A (es) Composiciones oftalmicas estabilizadas de omega 3.
EA200970944A1 (ru) Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов
NZ729021A (en) Extracellular matrix compositions
BR112015006929A2 (pt) sistemas de distribuição de droga biodegradável para liberação sustentada de proteínas
MX2020004730A (es) Implantes de liberacion sostenida para reducir la presion intraocular con un efecto de duracion prolongada.
WO2011137344A3 (en) Anti-s1p antibody treatment of patients with ocular disease
MX2015011418A (es) Tratamiento de enfermedades con nanofibras de poli-n-acetilglucosamina.
UY33153A (es) Formulación tópica oftálmica de péptidos
BR112019022912A2 (pt) Métodos e composições para tratar doenças oculares alérgicas
CY1123344T1 (el) Μεθοδοι αγωγης οφθαλμικων καταστασεων με ενα εμφυτευμα κατακρατημενης απελευθερωσης φαρμακων